Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Diabetes

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 30 articles:
HTML format



Single Articles


    March 2021
  1. FABRIS E, Ten Berg JM, Hermanides RS, Ottervanger JP, et al
    NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: Insight from the On-TIME II trial.
    Am Heart J. 2021;233:78-85.
    PubMed     Abstract available


    February 2021
  2. BERGER JH, Chen F, Faerber JA, O'Byrne ML, et al
    Adherence with lipid screening guidelines in standard- and high-risk children and adolescents.
    Am Heart J. 2021;232:39-46.
    PubMed     Abstract available


    December 2020
  3. SALAH HM, Al'Aref SJ, Khan MS, Al-Hawwas M, et al
    Effects of Sodium-Glucose Cotransporter 1 and 2 Inhibitors on Cardiovascular and Kidney Outcomes in Type 2 Diabetes: A Meta-analysis Update.
    Am Heart J. 2020 Dec 29. pii: S0002-8703(20)30406.
    PubMed     Abstract available


  4. SARRAJU A, Li J, Cannon CP, Chang TI, et al
    Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial.
    Am Heart J. 2020 Dec 20. pii: S0002-8703(20)30407.
    PubMed     Abstract available


    November 2020
  5. HAMO CE, Fonarow GC, Greene SJ, Vaduganathan M, et al
    Temporal Trends in Risk Profiles Among Patients Hospitalized for Heart Failure.
    Am Heart J. 2020 Nov 29. pii: S0002-8703(20)30397.
    PubMed     Abstract available


    October 2020
  6. COX ZL, Collins SP, Aaron M, Hernandez GA, et al
    Efficacy and Safety of Dapagliflozin in Acute Heart Failure: Rationale and Design of the DICTATE-AHF trial.
    Am Heart J. 2020 Oct 31. pii: S0002-8703(20)30357.
    PubMed     Abstract available


  7. SALAH HM, Al'Aref SJ, Khan MS, Al-Hawwas M, et al
    Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
    Am Heart J. 2020;232:10-22.
    PubMed     Abstract available


  8. GIBSON CM, Kastelein JJP, Phillips AT, Aylward PE, et al
    Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myoc
    Am Heart J. 2020 Oct 13. pii: S0002-8703(20)30335.
    PubMed     Abstract available


  9. WIGGERS H, Kober L, Gislason G, Schou M, et al
    The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 x 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with
    Am Heart J. 2020 Oct 8. pii: S0002-8703(20)30276.
    PubMed     Abstract available


    August 2020
  10. ELHARRAM M, Sharma A, White W, Bakris G, et al
    Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
    Am Heart J. 2020;229:40-51.
    PubMed     Abstract available


    June 2020
  11. GAO Y, Peterson E, Pagidipati N
    Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits.
    Am Heart J. 2020;224:47-53.
    PubMed     Abstract available


    April 2020
  12. LOWENSTERN A, Li S, Virani SS, Navar AM, et al
    Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry.
    Am Heart J. 2020;225:88-96.
    PubMed     Abstract available


    January 2020
  13. ROMAGUERA R, Salinas P, Brugaletta S, Gomez-Lara J, et al
    Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) trial: Rationale and study design.
    Am Heart J. 2020;222:174-182.
    PubMed    


    December 2019
  14. TRIPOLT NJ, Kolesnik E, Pferschy PN, Verheyen N, et al
    Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
    Am Heart J. 2019;221:39-47.
    PubMed     Abstract available


    November 2019
  15. DE FERRARI GM, Stevens SR, Ambrosio G, Leonardi S, et al
    Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
    Am Heart J. 2019;220:82-88.
    PubMed     Abstract available


    October 2019
  16. CHLEBUS K, Zdrojewski T, Gruchala M, Galaska R, et al
    Cardiovascular risk factor profiles in familial hypercholesterolemia patients with and without genetic mutation compared to a nationally representative sample of adults in a high-risk European country.
    Am Heart J. 2019;218:32-45.
    PubMed     Abstract available


  17. SHAVADIA JS, Zheng Y, Green JB, Armstrong PW, et al
    Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Am Heart J. 2019;218:92-99.
    PubMed     Abstract available


  18. PAGIDIPATI NJ, Zheng Y, Green JB, McGuire DK, et al
    Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.
    Am Heart J. 2019;219:47-57.
    PubMed     Abstract available


    August 2019
  19. BHATT AS, Luo N, Solomon N, Pagidipati NJ, et al
    International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.
    Am Heart J. 2019;218:57-65.
    PubMed     Abstract available


  20. RAY KK, Nicholls SJ, Ginsberg HD, Johansson JO, et al
    Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
    Am Heart J. 2019;217:72-83.
    PubMed     Abstract available


    May 2019
  21. MENTIAS A, Shantha G, Adeola O, Barnes GD, et al
    Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis.
    Am Heart J. 2019;214:158-166.
    PubMed     Abstract available


    January 2019
  22. SHARMA A, Mentz RJ, Granger BB, Heitner JF, et al
    Utilizing mobile technologies to improve physical activity and medication adherence in patients with heart failure and diabetes mellitus: Rationale and design of the TARGET-HF-DM Trial.
    Am Heart J. 2019;211:22-33.
    PubMed     Abstract available


  23. ZIAEIAN B, Hernandez AF, DeVore AD, Wu J, et al
    Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines-Heart Failure Registry.
    Am Heart J. 2019;211:1-10.
    PubMed     Abstract available


    September 2018
  24. PRADHAN AD, Paynter NP, Everett BM, Glynn RJ, et al
    Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
    Am Heart J. 2018;206:80-93.
    PubMed     Abstract available


    July 2018
  25. KOROL S, White M, O'Meara E, Tournoux F, et al
    A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial.
    Am Heart J. 2018 Jul 10. pii: S0002-8703(18)30203.
    PubMed     Abstract available


    June 2018
  26. ARNOLD SV, Echouffo-Tcheugui JB, Lam CS, Inzucchi SE, et al
    Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR).
    Am Heart J. 2018;203:25-29.
    PubMed     Abstract available


  27. GREEN JB, Hernandez AF, D'Agostino RB, Granger CB, et al
    Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.
    Am Heart J. 2018;203:30-38.
    PubMed     Abstract available


    April 2018
  28. BOWMAN L, Mafham M, Stevens W, Haynes R, et al
    ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes.
    Am Heart J. 2018;198:135-144.
    PubMed     Abstract available


    February 2018
  29. ANYANWAGU U, Mamza J, Donnelly R, Idris I, et al
    Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.
    Am Heart J. 2018;196:18-27.
    PubMed     Abstract available


    December 2017
  30. GO AS, Fan D, Sung SH, Inveiss AI, et al
    Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: The KP CHAMP study.
    Am Heart J. 2017;194:25-38.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: